Generic Abuse Deterrent Opioids: FDA Offers Tier-Based Testing Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
Draft guidance provides roadmap for testing generic solid oral opioid products; FDA's Califf notes difficulty in conducting post-market studies.
You may also be interested in...
Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling
US FDA wants to work with practitioners to develop suggested prescribing standards, which could then be used to create packaging requirements.
Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling
US FDA wants to work with practitioners to develop suggested prescribing standards, which could then be used to create packaging requirements.
Generic Abuse-Deterrent Opioids: Comparison To Brand Will Not Require Use Of Control
FDA final guidance recommends comparative pharmacodynamic studies for nasal and oral routes of abuse, simplifies statistical approach to show deterrence of generic is same as brand.